(3β)-2,3-dihydrolysergole | 114249-76-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 英文名称: (3β)-2,3-dihydrolysergole
• 英文别名: (3beta)-2,3-Dihydrolysergol；[(5aS,6aR,9R)-7-methyl-5,5a,6,6a,8,9-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]methanol
• CAS: 114249-76-2
• 化学式: C₁₆H₂₀N₂O
• 分子量: 256.348
• InChiKey: YEUJZVSROBECPL-UEKVPHQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3β)-2,3-dihydrolysergole 、 苯亚硒酸酐 、 四氢呋喃 、 吲哚 以97%的产率得到
  参考文献：
  名称：

  NINOMIYA, ICHIYA;HASHIMOTO, CHIYOMI;KIGUCHI, TOSHIKO;NAITO, TAKEAKI;BARTO+, J. CHEM. SOC. PERKIN TRANS. PT 1,(1990) N, C. 707-713

  摘要：

  DOI：
• 作为产物：
  描述：

  麦角醇 在 三乙基硅烷 、 三氟乙酸 作用下， 反应 3.0h， 以25%的产率得到(3β)-2,3-dihydrolysergole
  参考文献：
  名称：

  Ergolines as selective 5-HT1 agonists

  摘要：

  The synthesis and serotonin receptor subtype affinity of a series of ergolines are described. High selectivity for the 5-HT1 subtype was found with a number of 8-substituted (3 beta, 5 beta)-9,10-didehydro-6-methylergolines. The more potent and selective of these compounds increased the concentration of serotonin and decreased the concentration of 5-HIAA in rat brain and increased corticosterone concentration in rat serum. Oral administration of 13, (3 beta)-2,3-dihydrolysergine, produced long-lasting decreases in serotonin turnover. Compound 13 lacked substantial dopaminergic activity as measured by its effects on dopamine turnover in whole brain or striatum and its affinity for alpha-adrenergic binding sites was significantly less than for 5-HT1 binding sites. The increases in serum corticosterone concentrations produced by 13 were not blocked by the serotonin uptake inhibitor fluoxetine or by the serotonin synthesis inhibitor p-chlorophenylalanine, suggesting that 13 exerts its effects through direct stimulation of serotonin receptors.

  DOI：

  10.1021/jm00403a007

文献信息

• 2,3-Dihydroergolines for serotonergic function enhancement
  申请人：ELI LILLY AND COMPANY

  公开号：EP0306191A2

  公开（公告）日：1989-03-08

  A therapeutic method employing 2,3-dihydro­ergolines is disclosed. Said method enhances seroto­nergic function in the nervous system of a mammal in need thereof, thereby finding application in serotonin­mediated physiological manifestations including memory, depression, anxiety, pain and appetite. Also disclosed are pharmaceutical compositions containing said 2,3-­dihydroergolines in admixture with pharmaceutically acceptable diluents and carriers.

  本研究公开了一种使用 2,3-二氢麦角酚碱的治疗方法。该方法可增强有需要的哺乳动物神经系统中的血清素能功能，从而应用于血清素介导的生理表现，包括记忆、抑郁、焦虑、疼痛和食欲。此外，还公开了含有所述 2,3-二氢麦角林的药物组合物，该组合物与药学上可接受的稀释剂和载体混合。
• WARD, JOHN S.;FULLER, RAY W.;MERRITT, LEANDER;SNODDY, HAROLD D.;PASCHAL, +, J. MED. CHEM., 31,(1988) N 8, C. 1512-1519
  作者：WARD, JOHN S.、FULLER, RAY W.、MERRITT, LEANDER、SNODDY, HAROLD D.、PASCHAL, +

  DOI：——

  日期：——
• METHOD FOR TREATING STRESS WITH A PRECURSOR OF SEROTONIN
  申请人：Massachusetts Institute of Technology

  公开号：EP1253915A1

  公开（公告）日：2002-11-06
• NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
  申请人：Chen Chien-Hung

  公开号：US20120183600A1

  公开（公告）日：2012-07-19

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
• PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF
  申请人：ALS MOUNTAIN LLC

  公开号：US20140350064A1

  公开（公告）日：2014-11-27

  The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1) a therapeutically effective quantity of a first agent that is an AMPK activator; and (2) a therapeutically effective quantity of a second agent that possesses or maintains serotonin activity. A preferred composition comprises metformin hydrochloride and melatonin. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.